Regeneron Q4 2023 Earnings Report
Key Takeaways
Regeneron reported a 1% increase in revenue to $3.43 billion for Q4 2023. Excluding Ronapreve, revenue increased by 14%. GAAP diluted EPS was $10.19, and non-GAAP diluted EPS was $11.86. Key products like Dupixent and Libtayo saw significant sales growth. The company also submitted Dupixent sBLA for COPD and linvoseltamab BLA for multiple myeloma to the FDA.
Q4 2023 revenues increased 1% to $3.43 billion, or 14% excluding Ronapreve.
Dupixent global net sales increased 31% to $3.22 billion.
U.S. net sales for EYLEA HD and EYLEA were $1.46 billion, including $123 million from EYLEA HD.
Libtayo global net sales increased 44% to $244 million.
Regeneron
Regeneron
Regeneron Revenue by Segment
Forward Guidance
Regeneron provided its full year 2024 financial guidance, including GAAP R&D expenses of $4.820–$5.070 billion, non-GAAP R&D expenses of $4.300–$4.500 billion, GAAP SG&A expenses of $2.890–$3.090 billion, non-GAAP SG&A expenses of $2.500–$2.650 billion, COCM of $850–$910 million, capital expenditures of $825–$950 million, GAAP effective tax rate of 8%–10%, and non-GAAP effective tax rate of 10%–12%.
Positive Outlook
- Continued growth of Dupixent and EYLEA HD.
- Advancement of the R&D pipeline.
- Targeted commercial execution.
- Prudent deployment of capital to business development.
- Share repurchases.
Challenges Ahead
- Uncertainties related to clinical trials.
- Potential regulatory delays or restrictions.
- Competition from other drugs and product candidates.
- Impact of public health outbreaks.
- Risks associated with intellectual property litigation.